Erratum: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines (PLoS ONE (2013) 8:12 (e81587) DOI: 10.1371/journal.pone.0081587);A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: Implication for developing therapeutics and vaccines

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Du, Lanying ^a   Kou, Zhihua ^b   Ma, Cuiqing ^a   Tao, Xinrong ^c   Wang, Lili ^a   Zhao, Guangyu ^b   Chen, Yaoqing ^d   Yu, Fei ^a   Tseng, Chien Te K ^c   Zhou, Yusen ^b   Jiang, Shibo ^a,e  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MONTANIDE ISA 51 ADJUVANT; NEUTRALIZING ANTIBODY; RECOMBINANT CORONAVIRUS SPIKE PROTEIN 377-588 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MIDDLE EAST RESPIRATORY SYNDROME CORONOVIRUS INFECTION; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CORONAVIRUS; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FC; RECOMBINANT PROTEINS; RESPIRATORY TRACT INFECTIONS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINATION; VACCINES; VIRAL VACCINES;

EID: 84891885053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0278474     Document Type: Erratum

References (41)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814-1820.
2. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM (2013) Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 369: 587.
3. Mailles A, Blanckaert K, Chaud P, van der WS, Lina B, et al. (2013) First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 18: pii =20502.
4. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, et al. (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 369: 886.
5. The Health Protection Agency (HPA) UK Novel Coronavirus Investigation team (2013) Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 18: pii = 20427.
6. Cauchemez S, Van KM, Riley S, Donnelly C, Fraser C, et al. (2013) Transmission scenarios for Middle East respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. Euro Surveill 18: pii = 20503.
7. Breban R, Riou J, Fontanet A (2013) Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. The Lancet 382: 694-699.
8. Riley S, Fraser C, Donnelly CA, Ghani AC, bu-Raddad LJ, et al. (2003) Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300: 1961-1966.
9. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, et al. (2003) A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348: 1977-1985.
10. Lu L, Liu Q, Du L, Jiang S (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 15: 625-629.
11. Li F, Li WH, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868.
12. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495: 251-254.
13. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, et al. (2013) The spike-protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2 and is targeted by neutralizing antibodies. J Virol 87: 5502-5511.
14. Jiang S, Lu L, Du L, Debnath AK (2013) A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoVEMC. J Infect 66: 464-466.
15. Du L, Zhao G, Kou Z, Ma C, Sun S, et al. (2013) Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87: 9939-9942.
16. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, et al. (2013) The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 87: 9379-9383.
17. Lu G, Hu Y, Wang Q, Qi J, Gao F, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500: 227-231.
18. Wang N, Shi X, Jiang L, Zhang S, Wang D, et al. (2013) Structure of MERSCoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23: 986-993.
19. Chen Y, Rajashankar KR, Yang Y, Agnihothram SS, Liu C, et al. (2013) Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 87: 10777-10783
20. Wong SK, Li WH, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279: 3197-3201.
21. Chan JF, Li KS, To KK, Cheng VC, Chen H, et al. (2012) Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 65: 477-489.
22. Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, et al. (2013) Genetic characterization of Betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications on the origin of the novel Middle East Respiratory Syndrome Coronavirus. J Virol 87: 8638-8650.
23. Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, et al. (2013) Bilateral entry and release of Middle East respiratory syndrome-coronavirus induces profound apoptosis of human bronchial epithelial cells. J Virol 87: 9953-9958.
24. He Y, Zhou Y, Liu S, Kou Z, Li W, et al. (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324: 773-781.
25. He Y, Li J, Li W, Lustigman S, Farzan M, et al. (2006) Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 176: 6085-6092.
26. Du L, Zhao G, Chan CC, Sun S, Chen M, et al. (2009) Recombinant receptorbinding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393: 144-150.
27. Du L, He Y, Zhou Y, Liu S, Zheng BJ, et al. (2009) The spike protein of SARSCoV: a target for vaccine and therapeutic development. Nat Rev Micro 7: 226-236.
28. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.
29. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, et al. (2011) Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A 108: 4388-4393.
30. Zhang MY, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS (2008) Crossreactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen. Vaccine 27: 857-63.
31. Huang CJ, Lowe AJ, Batt CA (2010) Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market. Appl Microbiol Biotechnol 87: 401-410.
32. Hall RD, Gray JE, Chiappori AA (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 20: 22-31.
33. Pranchevicius MC, Vieira TR (2013) Production of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering. Bioengineered 4: 305-312.
34. Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365: 113.
35. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91: 9770-9774.
36. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186-2195.
37. Devitt E (2013) Lack of small animal model hinders MERS coronavirus research. Nat Med 8: 952.
38. de WE, Prescott J, Baseler L, Bushmaker T, Thomas T, et al. (2013) The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 8: e69127.
39. Munster VJ, de WE, Feldmann H (2013) Pneumonia from human coronavirus in a macaque model. N Engl J Med 368: 1560-1562.
40. Du L, Zhao G, Sun S, Zhang X, Zhou X, et al. (2013) A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS ONE 8: e53568.
41. Chan JF, Chan KH, Choi GK, To KK, Tse H, et al. (2013) Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 207: 1743-1752.